Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Active Biotech

5.29 SEK0.00 %28.8, 9.20
Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
0.00 %
+0.76 %
-22.43 %
-3.64 %
+15.00 %
-62.46 %
-79.96 %
-88.28 %
-98.72 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Read more
Market cap
139.45M SEK
Turnover
2.9K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.11
2026

Interim report Q3'26

11.2
2027

Annual report '26

6.5
2027

Interim report Q1'27

Press release20.08.2026, 13.22

Redeye: Active Biotech (Q2 Review): Record-Deals in Myelofibrosis in 2026

Active Biotech
Regulatory press release20.08.2026, 08.30

Active Biotech Interim Report Q2 2026

Active Biotech
Press release18.08.2026, 10.50

Active Biotech expands US collaboration to advance tasquinimod clinical development in myelofibrosis

Active Biotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release24.07.2026, 08.30

First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis

Active Biotech
Regulatory press release30.06.2026, 08.30

Number of shares and votes in Active Biotech

Active Biotech
Regulatory press release28.05.2026, 08.30

Active Biotech announces timetable for reverse share split

Active Biotech
Regulatory press release20.05.2026, 18.30

Annual General Meeting of Active Biotech AB

Active Biotech
Press release13.05.2026, 11.30

European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON

Active Biotech
Press release08.05.2026, 10.14

Redeye: Active Biotech (Q1 Review): Intensified Focus on Business Development

Active Biotech
Regulatory press release07.05.2026, 08.30

Active Biotech Interim Report Q1 2026

Active Biotech
Press release20.04.2026, 11.30

Active Biotech publishes results from the LION study on ocular absorption and distribution of laquinimod in the eye

Active Biotech
Regulatory press release17.04.2026, 14.30

NOTICE OF ANNUAL GENERAL MEETING

Active Biotech
Regulatory press release01.04.2026, 09.30

Annual Report 2025 Active Biotech AB (publ)

Active Biotech
Press release13.02.2026, 13.08

Redeye: Active Biotech (Q4 Review): Tasqinimod Recruiting Again

Active Biotech
Regulatory press release12.02.2026, 08.30

Active Biotech Year End Report 2025

Active Biotech
Press release10.02.2026, 11.30

Active Biotech receives positive feedback on its clinical study with tasquinimod in myelofibrosis

Active Biotech
Regulatory press release30.01.2026, 11.30

Number of shares and votes in Active Biotech

Active Biotech
Regulatory press release21.01.2026, 16.15

Active Biotech's nomination committee appointed

Active Biotech
Regulatory press release10.12.2025, 20.00

Active Biotech announces outcome in the rights issue

Active Biotech
Press release25.11.2025, 10.00

Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Active Biotech